Friday, April 22, 2016 10:04:13 AM
SIALYLATED GLYCOPROTEINS
"
[0101] In some embodiments, methods described herein are useful for controlling the sialylation of a reference polypeptide (e.g., a reference glycoprotein). In some embodiments, polypeptide (e.g., glycoprotein) preparations described herein have predetermined or target levels of glycans (e.g., branched glycans having a sialic acid on an .alpha.1,3 arm, and/or branched glycans having a sialic acid on an .alpha.1,6 arm, and/or branched glycans having a sialic acid on an .alpha.1,3 arm and on an .alpha.1,6 arm), where the predetermined levels are substantially similar to or different from (e.g., higher or lower than) levels of glycans (e.g., branched glycans having a sialic acid on an .alpha.1,3 arm, and/or branched glycans having a sialic acid on an .alpha.1,6 arm, and/or branched glycans having a sialic acid on an .alpha.1,3 arm and on an .alpha.1,6 arm) in a reference polypeptide product (e.g., glycoprotein product). Nonlimiting, exemplary reference glycoprotein products can include abatacept (Orencia.RTM., Bristol-Myers Squibb), abciximab (ReoPro.RTM., Roche), adalimumab (Humira.RTM., Bristol-Myers Squibb), aflibercept (Eylea.RTM., Regeneron Pharmaceuticals), alefacept (Amevive.RTM., Astellas Pharma), alemtuzumab (Campath.RTM., Genzyme/Bayer), basiliximab (Simulect.RTM., Novartis), belatacept (Nulojix.RTM., Bristol-Myers Squibb), belimumab (Benlysta.RTM., GlaxoSmithKline), bevacizumab (Avastin.RTM., Roche), canakinumab (Ilaris.RTM., Novartis), brentuximab vedotin (Adcetris.RTM., Seattle Genetics), certolizumab (CIMZIA.RTM., UCB, Brussels, Belgium), cetuximab (Erbitux.RTM., Merck-Serono), daclizumab (Zenapax.RTM., Hoffmann-La Roche), denileukin diftitox (Ontak.RTM., Eisai), denosumab (Prolia.RTM., Amgen; Xgeva.RTM., Amgen), eculizumab (Soliris.RTM., Alexion Pharmaceuticals), efalizumab (Raptiva.RTM., Genentech), etanercept (Enbrel.RTM., Amgen-Pfizer), gemtuzumab (Mylotarg.RTM., Pfizer), golimumab (Simponi.RTM., Janssen), ibritumomab (Zevalin.RTM., Spectrum Pharmaceuticals), infliximab (Remicade.RTM., Centocor), ipilimumab (Yervoy.TM., Bristol-Myers Squibb), muromonab (Orthoclone OKT3.RTM., Janssen-Cilag), natalizumab (Tysabri.RTM., Biogen Idea, Elan), ofatumumab (Arzerra.RTM., GlaxoSmithKline), omalizumab (Xolair.RTM., Novartis), palivizumab (Synagis.RTM., Medlmmune), panitumumab (Vectibix.RTM., Amgen), ranibizumab (Lucentis.RTM., Genentech), rilonacept (Arcalyst.RTM., Regeneron Pharmaceuticals), rituximab (MabThera.RTM., Roche), tocilizumab (Actemra.RTM., Genentech; RoActemra, Hoffman-La Roche) tositumomab (Bexxar.RTM., GlaxoSmithKline), and trastuzumab (Herceptin.RTM., Roche). “
Boing X 2
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM